protein biomarkers
Diagnostics Developer Early is Good Raises $4M in Seed Funding
The company will use the funds to complete clinical trials for its first product, BCDx, a laboratory-developed test for early bladder cancer detection.
OncoHost Raises $35M in Series C Financing
The Israeli firm will use the funds to expand its PROPHETIC trial and support the US commercial launch of the Prophet platform.
The firm obtained FDA breakthrough device designation in 2019 for its protein misfolding cyclic amplification technology and SynTap assay.
FDA Approves Agilent Technologies CDx for Breast Cancer Drug Verzenio
The CDx is the first FDA-approved immunohistochemistry assay to measure Ki-67 protein expression in the context of treatment with Eli Lilly's abemaciclib (Verzenio).
Synaps Dx Closes $10M Series A Round to Speed Commercialization of Alzheimer's Disease Test
The firm said the test has 95 percent sensitivity and specificity for diagnosing Alzheimer's disease based on autopsy-validated clinical data collected over many years.